ArticleCanadian journal of public health = Revue canadienne de sante publique2026
Evaluating equitable access based on sociodemographic predictors of nirmatrelvir-ritonavir use during the first year of availability in Ontario, Canada: A population-based ecological study.
Article in Canadian journal of public health = Revue canadienne de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNirmatrelvir-ritonavir is recommended to prevent severe outcomes due to SARS-CoV-2 infection in high-risk patients. Our objective was to determine if inequities existed in access to nirmatrelvir-ritonavir across sociodemographic groups.
methodsWe conducted a population-based ecological study of nirmatrelvir-ritonavir dispenses in Ontario, Canada, forward sortation areas (FSA) from April 4, 2022, to April 3, 2023. Our primary outcome was the FSA-level dispense rate of nirmatrelvir-ritonavir per 100,000 population. A negative binomial model was used to calculate crude and adjusted rate ratios with 95% confidence intervals (CIs) for nine sociodemographic variables (income, visible minority, essential worker, household size, education, citizenship, employment rate, social assistance, and language proficiency), adjusted for seven demographic/clinical population-level variables (age, sex, comorbidities, immunocompromised, COVID-19 vaccination, long-term care residents, and percent SARS-CoV-2 PCR test positivity).
resultsThe final cohort included 513 FSAs, 12,911,594 residents-127,123 (0.98%) who received and 12,784,471 (99.02%) who did not receive nirmatrelvir-ritonavir. There was an 18-fold variation across FSAs, 133-2417 prescriptions per 100,000 population. In the adjusted model, dispensing rates were significantly lower in regions with higher proportions of residents with low income (adjusted rate ratio (RR
conclusionThis province-wide study revealed small inequities in nirmatrelvir-ritonavir dispensing across Ontario neighborhoods with lower income and lower post-secondary education populations associated with less nirmatrelvir-ritonavir use. The findings highlight the importance of addressing barriers for equitable access to therapeutics for future pandemics.
Indexed as
Identifiers
41973385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.